|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期2011-01-01 |
靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期1950-09-01 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期1946-05-06 |
Open Label Clinical Study to Evaluate the Safety and Efficacy of ProvayBlueTM (Methylene Blue) for the Treatment of Acquired Methemoglobinemia
This is an open label, uncontrolled, Phase 4 study including 10 patients who present in hospital/urgent care setting with acquired methemoglobinemia. The population may include pediatric and adult patients (males and females of all ages are included).
The study will run in both the EU and the US. The aim of the study is to confirm safety and efficacy of ProvayBlueTM for the treatment of acquired methemoglobinemia and has been requested by the US-FDA as a Post-Marketing requirements.
100 项与 Provepharm SAS 相关的临床结果
0 项与 Provepharm SAS 相关的专利(医药)
100 项与 Provepharm SAS 相关的药物交易
100 项与 Provepharm SAS 相关的转化医学